Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularisGlobeNewsWire • 11/11/22
Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European CommissionGlobeNewsWire • 11/10/22
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infantsGlobeNewsWire • 11/04/22
Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance BoostInvestors Business Daily • 10/28/22
Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”Business Wire • 10/26/22
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years oldGlobeNewsWire • 10/11/22
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetesPRNewsWire • 10/06/22
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularisGlobeNewsWire • 09/28/22
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASDBusiness Wire • 09/19/22
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infantsGlobeNewsWire • 09/16/22